The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Expansion In Market Value Is Forecasted For The Shingrix (Zostavax) Market Between 2026 And 2030?
Historical growth stemmed from a heightened understanding of shingles’ potential complications, the rise in the global aging population, previous limitations associated with live attenuated vaccines, the broadening of immunization guidelines for older adults, and an increasing rate of physician recommendations.
The anticipated growth during the forecast period is fueled by several factors, including elevated targets for adult vaccination coverage, increased healthcare expenditure on preventative measures, the expansion of recombinant vaccine development, a rise in government-backed immunization programs, and a sharpened focus on alleviating the burden of post-herpetic neuralgia. Key developments expected during this period involve the wider adoption of recombinant vaccine technologies, a growing emphasis on adult immunization initiatives, an escalating need for durable shingles protection, the broadening of cold-chain optimized vaccine distribution networks, and a heightened commitment to ensuring vaccine safety and effectiveness.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20264&type=smp
What Factors Are Contributing To The Growth Of The Shingrix (Zostavax) Market?
The increasing embrace of vaccination is projected to drive the expansion of the shingrix (zostavax) market. Vaccination involves giving a vaccine to encourage the body’s immune system to identify and combat particular disease-causing agents. This rising acceptance of vaccination stems from heightened understanding of its efficacy in preventing illnesses, decreasing the burden of disease, and the creation of secure and readily available vaccines. Furthermore, public health efforts, better healthcare facilities, and worldwide immunization programs also play a role in its broad adoption. Shingrix (Zostavax) is valuable for vaccination as it offers robust defense against shingles and related issues. It proves especially advantageous for individuals over 50 years of age, substantially lowering the likelihood of shingles recurring and of developing post-herpetic neuralgia. As an illustration, a study published in May 2024 by the Journal of the American Medical Association (JAMA), a US-based peer-reviewed medical journal, indicated that shingles vaccinations covered by Medicare Part D saw a 46% rise in the year subsequent to the IRA policy’s introduction in January 2023. Consequently, the expanding uptake of vaccination is fueling the growth of the shingrix (zostavax) market.
Which Segment Categories Are Included In The Shingrix (Zostavax) Market Segment Analysis?
The shingrix (zostavax) market covered in this report is segmented –
1) By Formulation: Recombinant Vaccine (Shingrix), Live Attenuated Vaccine (Zostavax)
2) By Indication: Shingles Prevention, Post-Herpetic Neuralgia
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy
What Market Trends Are Affecting The Shingrix (Zostavax) Market?
Leading companies within the shingrix (zostavax) market are concentrating on developing advanced solutions, such as non-live, recombinant subunit adjuvanted vaccines. This focus aims to address the growing demand for safer and more effective immunization, driven significantly by age-related immune system decline and the necessity for alternatives for immunocompromised individuals. A non-live, recombinant subunit adjuvanted vaccine integrates specific protein components (antigens) from a pathogen, along with an adjuvant to amplify the immune response, contrasting with traditional live-attenuated vaccines that utilize weakened whole viruses. For instance, in 2023, GSK plc, a UK-based biopharmaceutical corporation, launched Shingrix (Recombinant Zoster Vaccine, RZV) in India. This vaccine is non-live, administered intramuscularly in two doses, and contains the glycoprotein E antigen plus GSK’s proprietary AS01B adjuvant system. Shingrix stimulates a powerful and enduring immune response, overcoming the age-related reduction in immunity in older adults, and offers very high efficacy (up to ~97%).
Who Are The Active Companies Shaping The Shingrix (Zostavax) Market?
Major companies operating in the shingrix (zostavax) market are GSK plc
Get The Full Shingrix (Zostavax) Market Report:
https://www.thebusinessresearchcompany.com/report/shingrix-zostavax-global-market-report
Which Region Is The Leading Market For The Shingrix (Zostavax) Market?
North America was the largest region in the shingrix (zostavax) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingrix (zostavax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Shingrix (Zostavax) Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/shingrix-zostavax-global-market-report
Browse Through More Reports Similar to the Global Shingrix (Zostavax) Market 2026, By The Business Research Company
Varenicline Market Report 2026
https://www.thebusinessresearchcompany.com/report/varenicline-global-market-report
Feed Premix Market Report 2026
https://www.thebusinessresearchcompany.com/report/feed-premix-global-market-report
Zinc Battery Market Report 2026
https://www.thebusinessresearchcompany.com/report/zinc-battery-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model